V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante

Registro Español de Trasplante Hepático [consultado 8 Oct 2014]. Disponible en: http://www.sethepatico.org James, 1999, Guidelines for selection of patients for liver transplantation in the era of donor-organ shortage, Lancet, 354, 1636, 10.1016/S0140-6736(99)90002-8 Neuberger, 2008, Selection of patients for liver transplantation and allocation of donated livers in the UK, Gut, 57, 252, 10.1136/gut.2007.131730 Nachmany, 2013, A validated model for predicting outcome after liver transplantation: Implications on transplanting the extremely sick, Transplant Int, 26, 1108, 10.1111/tri.12171 Martin, 2014, Evaluation for liver transplantation in adults: 2013 Practice guideline by the American Association or the study of Liver Diseases and the American Society of Transplantation, Hepatology, 59, 1144, 10.1002/hep.26972 Disponible en: http://www.ont.es/infesp/Paginas/DatosdeDonacionyTrasplante.aspx [consultado 8 Oct 2014]. Knight, 2012, Implications of changing the minimal survival benefit in liver transplantation, Liver Transpl., 18, 549, 10.1002/lt.23380 Keller, 2014, Ethical considerations surrounding survival benefit-based liver allocation, Liver Transpl, 20, 140, 10.1002/lt.23780 Cuervas-Mons, 2006, Receptores de trasplante hepático de alto riesgo, Gastroenterol Hepatol, 29, 65 Briceño, 2013, Donor-recipient matching: Myths and realities, J Hepatol, 58, 811, 10.1016/j.jhep.2012.10.020 Merion, 2004, When is a patient too well and when is a patient too sick for a liver transplant?, Liver Transpl., 10, S69, 10.1002/lt.20265 Freeman, 2012, Should we change the priority for liver allocation for patients with the highest MELD score?, Hepatology, 55, 14, 10.1002/hep.24775 Sharma, 2012, End-stage liver disease candidates at the highest MELD scores have higher waitlist mortality than status-1 A candidates, Hepatology, 55, 192, 10.1002/hep.24632 Abouljoud, 2014, Sicker patients with end-stage liver disease cost more: A quick fix. An editorial on assessing variation in the costs of care among patients awaiting liver transplantation, Am J Transpl, 14, 9, 10.1111/ajt.12498 Axelrod, 2014, Assessing variation in the costs of care among patients awaiting liver transplantation, Am J Transplant, 14, 70, 10.1111/ajt.12494 Bruns, 2014, Peter Schemmer prediction of postoperative mortality in liver transplantation in the era of MELD-based liver allocation: A multivariate analysis, Plos One, 9, e98782, 10.1371/journal.pone.0098782 Kristin, 2013, Predicting Survival after Liver Transplantation Based on Pre-Transplant MELD Score: a Systematic Review of the Literature, Plos One, 8, e80661, 10.1371/journal.pone.0080661 De la Mata, 2006, Model for end-stage liver disease score-based allocation of donors for liver transplantation: A Spanish multicenter experience, Transplantation., 82, 1429, 10.1097/01.tp.0000244559.60989.5a Northup, 2015, Excess mortality on the liver transplant waiting list: Unintended policy consequences and model for end-stage liver disease (MELD) inflation, Hepatology, 61, 285, 10.1002/hep.27283 Schaubel, 2008, The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality, Am J Transplant, 8, 419, 10.1111/j.1600-6143.2007.02086.x Schaubel, 2009, Survival benefit-based deceased-donor liver allocation, Am J Transplant, 9, 970, 10.1111/j.1600-6143.2009.02571.x Rana, 2008, Survival outcomes following liver transplantation (SOFT) score: A novel method to predict patient survival following liver transplantation, Am J Transplant, 8, 2537, 10.1111/j.1600-6143.2008.02400.x Rana, 2013, The survival outcomes following liver transplantation (SOFT) score: Validation with contemporaneous data and stratification of high-risk cohorts, Clin Transplant, 27, 627, 10.1111/ctr.12181 Desai, 2004, Predicting outcome after liver transplantation: Utility of the model for end-stage liver disease and a newly derived discrimination function, Transplantation., 77, 99, 10.1097/01.TP.0000101009.91516.FC Burroughs, 2006, 3-month and 12-month mortality after first liver transplant in adults in Europe: Predictive models for outcome, Lancet., 367, 225, 10.1016/S0140-6736(06)68033-1 Briceño, 2014, Use of artificial intelligence as an innovative donor-recipient matching model for liver transplantation: Results from a multicenter Spanish study, J Hepatol., 61, 1020, 10.1016/j.jhep.2014.05.039 Rodriguez-Castro, 2012, Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: a systematic review, Transplantation, 94, 1145, 10.1097/TP.0b013e31826e8e53 Ponziani, 2014, Portal vein thrombosis and liver transplantation: implications for waiting list period, surgical approach, early and late follow-up, Transplant Rev, 28, 92, 10.1016/j.trre.2014.01.003 Francoz, 2012, Portal vein thrombosis, cirrhosis, and liver transplantation, J Hepatol, 57, 203, 10.1016/j.jhep.2011.12.034 Huard, 2012, Management of anticoagulation for portal vein thrombosis in individuals with cirrhosis: A systematic review, International Journal of Hepatology, 8, 672986 Francoz, 2005, Splanchnic vein trombosis in candidates for liver transplantation: usefulness of screening and anticoagulation, Gut, 54, 691, 10.1136/gut.2004.042796 Nonami, 1992, The incidente of portal vein trombosis at liver transplantation, Hepatology, 16, 1195, 10.1002/hep.1840160515 Stieber, 1991, The spectrum of portal vein thrombosis in liver transplantation, Ann Surg, 213, 199, 10.1097/00000658-199103000-00003 Gayowski, 1996, A high incidence of native portal vein thrombosis in veterans undergoing liver transplantation, J Surg Res, 60, 333, 10.1006/jsre.1996.0053 Yerdel, 2000, Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome, Transplantation, 69, 1873, 10.1097/00007890-200005150-00023 Jamieson, 2000, Changing perspectives in portal vein thrombosis and liver transplantation, Transplantation, 69, 1772, 10.1097/00007890-200005150-00006 Charco, 2005, Portal vein thrombosis in liver transplantation, Transplant Proc, 37, 3904, 10.1016/j.transproceed.2005.09.120 Bauer, 2006, The role of TIPS for portal vein patency in liver transplant patients with portal vein thrombosis, Liver Transpl, 12, 1544, 10.1002/lt.20869 Amitrano, 2000, Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis, Hepatology, 31, 345, 10.1002/hep.510310213 Amitrano, 2004, Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis, J Hepatol, 40, 736, 10.1016/j.jhep.2004.01.001 Davidson, 1994, Incidence, risk factors, management, and outcome of portal vein abnormalities at orthotopic liver transplantation, Transplantation, 57, 1174, 10.1097/00007890-199404270-00006 Egawa, 2006, Single center experience of 39 patients with preoperative portal vein thrombosis among 404 adult living donor liver transplantations, Liver Transpl, 12, 1512, 10.1002/lt.20777 Dumortier, 2002, Eversion thrombectomy for portal vein thrombosis during liver transplantation, Am J Transpl, 2, 934, 10.1034/j.1600-6143.2002.21009.x Senzolo, 2012, Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis, Liver Int, 32, 919, 10.1111/j.1478-3231.2012.02785.x Francoz, 2005, Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation, Gut, 54, 691, 10.1136/gut.2004.042796 Amitrano, 2010, Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis, J Clin Gastroenterol, 44, 448, 10.1097/MCG.0b013e3181b3ab44 Zecchini, 2010, Anticoagulant therapy is safe and effective in preventing portal vein thrombosis (PVT) in advanced cirrhotic patients: A prospective randomized controlled study, J Hepatol, 52, S459, 10.1016/S0168-8278(10)61187-7 Han, 2011, Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis, J Hepatol, 54, 78, 10.1016/j.jhep.2010.06.029 Luca, 2011, Short and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis, Gut, 60, 846, 10.1136/gut.2010.228023 Senzolo, 2006, Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation, Aliment Pharmacol Ther, 23, 767, 10.1111/j.1365-2036.2006.02820.x Robles, 2004, Eversion thromboendovenectomy in organized portal vein thrombosis during liver transplantation, Clin Transplant., 18, 79, 10.1111/j.1399-0012.2004.00120.x Nikitin, 2009, Twenty years’ follow-up of portal vein conduits in liver transplantation, Liver Transpl, 15, 400, 10.1002/lt.21698 Hibi, 2014, When and why portal vein thrombosis maters in liver transplantation. A critical audit of 174 cases, Ann Surg, 259, 760, 10.1097/SLA.0000000000000252 Bangui, 2011, Caval inflow to the graft for liver transplantation in patients with diffuse portal vein thrombosis. A 12-year experience, Ann Surg, 254, 1008, 10.1097/SLA.0b013e31822d7894 Englesbe, 2010, Portal vein thrombosis and liver transplant survival benefit, Liver Transpl, 16, 999, 10.1002/lt.22105 Wu, 2011, Clinical analysis and strategy for liver transplantation in patients with pre-existing portal vein thrombosis, Chang Gung Medi J, 34, 426 Moon, 2014, Management of extensive nontumorous portal vein trombosis in adult living donor liver transplantation, Transplantation, 97, S23, 10.1097/01.tp.0000446270.20934.05 World Health Organization [consultado 8 Oct 2014]. Disponible en: www.who.int/mediacentre/factsheets/fs311/en Bilbao I, Guevara A, Dopazo D, Castells L, Lázaro JL, Sapisochin G, Campos I, Charco R. Abastract y Comunicación oral. Obesidad y síndrome metabólico tras el trasplante hepático a lo largo de 15 años [consultado 8 Oct 2014]. Disponible en: https://www.setrasplante.org/SET Madrid 2012 Bilbao I, Castells L, Dopazo C, Lázaro J, Caralt M, de la Serna S, Moreira C, Charco R. Abstract y comunicación oral n.̊ 26. Impacto del índice de masa corporal en la supervivencia a largo plazo de los pacientes trasplantados hepáticos [consultado 8 Oct 2014]. Disponible en: https://www.setrasplante.org/SET Orci, 2013, The impact of wait list body mass index changes on the outcome alter liver transplantation, Transpl Int, 26, 170, 10.1111/tri.12017 Saab, 2015, The impact of obesity on patient survival in liver transplant recipients: A meta-analysis, Liver Int, 35, 164, 10.1111/liv.12431 Montejo González, 2008, Trasplante hepático. Implicaciones nutricionales, Nutr Hosp, 23, 34 Le Cornu, 2000, A prospective randomized study of preoperative nutritional supplementation in patients awaiting elective orthotopic liver transplantation, Transplantation, 69, 1364, 10.1097/00007890-200004150-00026 Tanaka, 2013, The impact of obesity as determined by modified body mass index on long-term outcome after liver transplantation: Canadian single-center experience, Transplant Proc, 45, 2288, 10.1016/j.transproceed.2012.11.009 Global Database on Body Mass Index — World Health Organization [consultado 8 Oct 2014]. Disponible en: www.who.int/bmi/index.jsp?introPage=intro_3.html Lin, 2013, Laparoscopic sleeve gastrectomy is safe and efficacious for pretransplant candidates, Surg Obes Relat Dis, 9, 653, 10.1016/j.soard.2013.02.013 Choudhary, 2013, Innovative approach using an intragastric balloon for weight loss in a morbidly obese patient undergoing liver transplantation, Liver Transpl, 19, 235, 10.1002/lt.23567 Weingarten, 2011, Nonalcoholic steatohepatitis (NASH) does not increase complications after laparoscopic bariatric surgery, Obes Surg, 21, 1714, 10.1007/s11695-011-0521-z Mosko, 2011, Increased perioperative mortality following bariatric surgery among patients with cirrhosis, Clin Gastroenterol Hepatol, 9, 897, 10.1016/j.cgh.2011.07.007 Heimbacha, 2013, Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease, American Journal of Transplantation, 13, 363, 10.1111/j.1600-6143.2012.04318.x Butte, 2007, Sleeve gastrectomy as treatment for severe obesity after orthotopic liver transplantation, Obes Surg, 17, 1517, 10.1007/s11695-008-9432-z Al-Nowaylati, 2013, Gastric bypass after liver transplantation, Liver Transpl, 19, 1324, 10.1002/lt.23734 Anastasio, 2013, Overweight in liver transplant recipients, Rev Col Bras Cir, 40. Charlton, 2009, Obesity, hyperlipidemia, and metabolic syndrome, Liver Transpl, 15, S83, 10.1002/lt.21914 Kouz, 2014, Weight gain after orthotopic liver transplantation: Is NAFLD cirrhosis a risk factor for greater weight gain?, Liver Transpl, 20, 1266, 10.1002/lt.23951 Anastácio, 2012, Overweight, obesity and weight gain un to three years after liver transplantation, Nutr Hosp, 27, 1351 Hakeem, 2013, Increased morbidity in overweight and obese liver transplant recipients: A single-center experience of 1325 patients from the United Kingdom, Liver Transpl, 19, 551, 10.1002/lt.23618 Perez-Proto, 2013, Comparable graft and patient survival in lean and obese liver transplant recipients, Liver Transpl, 19, 907, 10.1002/lt.23680 Shinghal, 2015, Impact of recipient morbid obesity on outcomes after liver transplantation, Transpl Int, 28, 148, 10.1111/tri.12483 Foster, 2012, Metabolic alterations following visceral fat removal and expansion: Beyond anatomic location, Adipocyte, 1, 192, 10.4161/adip.21756 Dare, 2014, Additive effect of pretransplant obesity, diabetes, and cardiovascular risk factors on outcomes after liver transplantation, Liver Transpl, 20, 281, 10.1002/lt.23818 Manoushagian, 2014, Evaluation of solid organ transplant candidates for coronary artery disease, Am J Transpl, 4, 2228, 10.1111/ajt.12915 Dare, 2014, Additive effect of pretransplant obesity, diabetes and cardiovascular risk factors on outcomes after liver transplantation, Liver Transpl, 20, 281, 10.1002/lt.23818 Gologorsky, 2013, Coronary artery disease and its risk factors in patients presenting for liver transplantation, J Clin Anesth., 25, 618, 10.1016/j.jclinane.2013.06.001 Carey, 1995, The prevalence of coronary artery disease in liver transplant candidates over age 50, Transplantation, 59, 859, 10.1097/00007890-199503270-00010 Hardwaj, 2013, Coronary events in patients undergoing orthotopic liver transplantation: Perioperative evaluation and management, Clin Transpl, 27, E207, 10.1111/ctr.12113 Lentine, 2012, Cardiac disease evaluation and management among kidney and liver transplantation candidates: A scientific statement from the American Heart Association and the American College of Cardiology Foundation, Circulation, 61, 7 Cassagneau, 2012, Prognostic value of preoperative coronary computed tomography in patients treated by orthotopic liver transplantation, Eur J Gastroenterol Hepatol, 24, 558, 10.1097/MEG.0b013e3283522df3 Ehtisham, 2010, Coronary artery disease in orthotopic liver transplantation: Pretransplant assessment and management, Liver Transpl, 16, 550, 10.1002/lt.22035 Nicolau-Raducu, 2015, Adverse cardiac events after orthotopic liver transplantation: A cross-sectional study in 389 consecutive patients, Liver Transpl, 21, 13, 10.1002/lt.23997 Herrero, 2009, De novo malignancies following liver transplantation: Impact and recommendations, Liver Transpl, 15, S90, 10.1002/lt.21898 Watt, 2010, Evolution of causes and risk factors for mortality post-liver transplant: Results of the NIDDK long-term follow-up study, Am J Transplant., 10, 1420, 10.1111/j.1600-6143.2010.03126.x Rubin, 2013, Long-term outcome of long-term liver transplant survivors, Transplant Int., 26, 740, 10.1111/tri.12118 Herrero, 2011, Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: The effect of smoking withdrawal, Liver Transpl., 17, 402, 10.1002/lt.22247 Wimmer, 2013, Impact of cyclosporine versus tacrolimus on the incidence of de novomalignancy following liver transplantation: A single center experience with 609 patients, Transplant Int, 26, 999, 10.1111/tri.12165 Sampaio, 2012, Posttransplant malignancies in solid organ adult recipients, Transplantation, 94, 990, 10.1097/TP.0b013e318270bc7b Tjon, 2010, Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: An association with C2 monitoring and recipient age, Liver Transpl., 16, 837, 10.1002/lt.22064 Swinnen, 1990, Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients, N Engl J Med., 323, 1723, 10.1056/NEJM199012203232502 Abdelmalek, 2012, Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: A randomized trial, Am J Transplant., 12, 694, 10.1111/j.1600-6143.2011.03919.x Knoll, 2014, Effect of sirolimus on malignancy and survival after kidney transplantation: Systematic review and meta-analysis of individual patient data, BMJ., 349, g6679, 10.1136/bmj.g6679 Euvrard, 2006, Skin cancers after liver transplantation: What to do?, J Hepatol., 44, 27, 10.1016/j.jhep.2005.10.010 Benlloch, 2004, De novo internal neoplasms after liver transplantation: Increased risk and aggressive behavior in recent years?, Am J Transplant., 4, 596, 10.1111/j.1600-6143.2004.00380.x Stallone, 2005, Sirolimus for Kaposi's sarcoma in renal-transplant recipients, N Engl J Med., 352, 1317, 10.1056/NEJMoa042831 Reshef, 2011, Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder, Am J Transplant., 11, 336, 10.1111/j.1600-6143.2010.03387.x Euvrard, 2012, Sirolimus and secondary skin-cancer prevention in kidney transplantation, N Engl J Med., 367, 329, 10.1056/NEJMoa1204166 Gomez-Camarero, 2007, Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms, Transplantation, 84, 786, 10.1097/01.tp.0000280549.93403.dd Berenguer, 2012, Spanish Society of Liver Transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation, Liver Int Internet., 32, 712, 10.1111/j.1478-3231.2011.02731.x Samonakis, 2012, Immunosuppression and HCV recurrence after liver transplantation, J Hepatol 56, 973, 10.1016/j.jhep.2011.06.031 Kwo, 2014, An Interferon-free antiviral regimen for HCV after liver transplantation, N Engl J Med., 371, 2375, 10.1056/NEJMoa1408921 Veldt, 2008, Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection, Am J Transplant., 8, 2426, 10.1111/j.1600-6143.2008.02362.x Rodríguez-Perálvarez, 2014, Liver transplantation, Curr Opin Organ Transplant., 19, 253, 10.1097/MOT.0000000000000069 lvarez, 2013, Early tacrolimus exposure after liver transplantation: Relationship with moderate/severe acute rejection and long-term outcome, J Hepatol., 58, 262, 10.1016/j.jhep.2012.09.019 Cholongitas, 2014, Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: A systematic review, Transplant Int., 27, 1039, 10.1111/tri.12372 Klintmalm, 2014, The role of mTOR Inhibitors in liver transplantation: Reviewing the evidence, Journal of Transplantation, 2014, 1, 10.1155/2014/845438 Clavien, 2011, Recommendations for liver transplantation for hepatocellular carcinoma: An international consensus conference report, Lancet Oncology, 13, e11, 10.1016/S1470-2045(11)70175-9 Gomez-Martin, 2011, Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation, Liver Transpl., 18, 45, 10.1002/lt.22434 Stallone, 2011, Sirolimus and proteinuria in renal transplant patients: Evidence for a dose-dependent effect on slit diaphragm-associated proteins, Transplantation, 91, 997, 10.1097/TP.0b013e318211d342 Ojo, 2003, Chronic renal failure after transplantation of a nonrenal organ, N Engl J Med., 349, 931, 10.1056/NEJMoa021744 Herrero, 1999, Conversion of liver transplant recipients on cysclosporine with renal impairment to mycophenolate mofetil, Liver Transpl Surg, 5, 414, 10.1002/lt.500050513 Ponton, 2010, Improvement of renal function after conversion to mycophenolate mofetil combined with low-level calcineurin inhibitor in liver transplant recipients with chronic renal dysfunction, Transplant Proc, 42, 656, 10.1016/j.transproceed.2010.02.006 Planas, 2004, Mycophenolate mofetil can be used as monotherapy late after liver transplantation, Am J Transplant., 4, 1650, 10.1111/j.1600-6143.2004.00556.x De Simone, 2012, Everolimus with reduced tacrolimus improves renal function in de novoliver transplant recipients: A randomized controlled trial, Am J Transplant., 12, 3008, 10.1111/j.1600-6143.2012.04212.x Vitale, 2014, A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list, J Hepatol., 60, 290, 10.1016/j.jhep.2013.10.010 Mehta, 2013, Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: Implications for the current organ allocation policy, Liver Transplant, 19, 1343, 10.1002/lt.23753 Clavien, 2012, Recommendations for liver transplantation for hepatocellular carcinoma: An international consensus conference report, Lancet Oncol., 13, e11, 10.1016/S1470-2045(11)70175-9 Ramos, 2013, Grado de homogeneidad de los grupos españoles de trasplante hepático en el tratamiento del hepatocarcinoma, Med Clin (Barc), 141, 406, 10.1016/j.medcli.2013.03.009 Toso, 2012, A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list, Hepatology, 56, 150, 10.1002/hep.25603 Toso, 2014, Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list, Transpl Int., 27, 686, 10.1111/tri.12323 Halazun, 2014, Standing the test of time: Outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment, Hepatology, 60., 1957, 10.1002/hep.27272 Schlansky, 2014, Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: A cohort study using the United Network for Organ Sharing registry, Liver Transpl., 20, 1045, 10.1002/lt.23917 Samoylova, 2014, Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation, Liver Transpl., 20, 937, 10.1002/lt.23902 Bitterman, 2014, Waiting time and explant pathology in transplant recipients with hepatocellular carcinoma: A novel study using national data, Am J Transplant, 14, 1657, 10.1111/ajt.12774 Galuppo, 2013, The role of bridging therapy in hepatocellular carcinoma, Int J Hepatol, 1, 10.1155/2013/419302 Majno, 2011, Is the treatment of hepatocellular carcinoma on the waiting list necessary?, Liver Transpl, 17, 10.1002/lt.22391 Cescon, 2013, Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate, J Hepatol, 58, 609, 10.1016/j.jhep.2012.09.021 Martin, 2006, Radiofrequency thermal ablation of hepatocellular carcinoma before liver transplantation—a clinical and histological examination, Clin Transpl, 20, 695, 10.1111/j.1399-0012.2006.00538.x Pompili, 2005, Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence, Liver Transpl, 11, 1117, 10.1002/lt.20469 DuBay, 2011, Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation, HPB (Oxford), 13, 24, 10.1111/j.1477-2574.2010.00228.x Roberts, 2010, Hepatocellular carcinoma: Ablate and wait versus rapid transplantation, Liver Transpl, 16, 925, 10.1002/lt.22103 Vitale, 2010, Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety, Hepatology, 51, 165, 10.1002/hep.23260 Truesdale, 2011, Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant, Transpl Int, 4, 991, 10.1111/j.1432-2277.2011.01299.x Kneteman, 2011, Tools for monitoring patients with hepatocellular carcinoma on the waiting list and after liver transplantation, Liver Transpl, 17, S117, 10.1002/lt.22334 Duvoux, 2012, Liver transplantation for hepatocellular carcinoma: A model including alfa-fetoprotein improves the performance of Milan Criteria, Gastroenterology, 143, 986, 10.1053/j.gastro.2012.05.052 Hameed, 2014, Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan Criteria, Liver Transpl, 20, 945, 10.1002/lt.23904 Merani, 2011, The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma, J Hepatol, 55, 814, 10.1016/j.jhep.2010.12.040 Cherqui, 2009, Liver resection for transplantable hepatocellular carcinoma: Long-term survival and role of secondary liver transplantation, Ann Surg, 250, 738, 10.1097/SLA.0b013e3181bd582b Llovet, 2002, Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation, Gut, 50, 123, 10.1136/gut.50.1.123 Sala, 2004, High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation, Liver Transpl, 10, 1294, 10.1002/lt.20202 Scatton, 2008, Hepatocellular carcinoma developed on compensated cirrhosis: Resection as a selection tool for liver transplantation, Liver Transpl, 14, 779, 10.1002/lt.21431